Survivorship: Managing Your Health for the Long Term
At a Glance
Managing Adult-Onset Immunodeficiency (AOID) long-term requires avoiding live vaccines and environmental infection triggers like potting soil. Regular blood tests are necessary to monitor autoantibody levels, while new fevers or skin changes should be evaluated by a doctor immediately.
Living with Adult-Onset Immunodeficiency (AOID) is a marathon, not a sprint. Because this is a chronic, relapsing condition, your focus will shift from “curing” the disease to maintaining long-term stability and vigilance [1]. With the right care team and monitoring plan, many patients can manage their symptoms and lead full lives.
Infection Prevention and Vaccine Safety
Because you have an immunodeficiency and may be on B-cell depleting therapies, you must take active steps to prevent new infections:
- Vaccine Rules: You must avoid all “live” vaccines, such as the nasal flu spray (FluMist), the measles/mumps/rubella (MMR) vaccine, or the yellow fever vaccine [2]. These can cause severe infections in your body. However, you should stay up to date on “dead” or recombinant vaccines (like the injectable flu shot or pneumonia vaccines), though your body may produce a blunted response to them while on rituximab.
- Environmental Triggers: Nontuberculous mycobacteria (NTM) and certain fungi live in soil, dust, and water. Avoid high-risk exposures like gardening with potting soil, using hot tubs, or cleaning humidifiers without proper protective gear (N95 mask and gloves) [3].
The Importance of Lifelong Surveillance
Even when you feel well, your immune system requires regular check-ins. AOID has a “relapsing-remitting” pattern, meaning infections can return if your autoantibody levels rise [1].
- Autoantibody Titers: Doctors use specialized tests (like ELISA) to monitor the level of anti-IFN-γ antibodies in your blood.
- Inflammatory Markers: Regular blood work to check your C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) helps your team detect “silent” inflammation before it becomes a major problem [2].
Long-Term Risks: Contextualizing Lymphoma
Research indicates that patients with AOID have a slightly elevated risk of developing certain cancers, specifically B-cell lymphoma, compared to the general population [4]. This is not a guarantee that you will get cancer; rather, it is a known consequence of the constant immune stimulation and the underlying autoimmune process [5]. Your doctors are aware of this and will proactively monitor you, typically through regular physical exams checking for swollen lymph nodes and routine blood work.
“Red-Flag” Symptoms: When to Call Your Doctor
Because infections can escalate quickly, you should contact your medical team immediately if you experience:
- Unexplained Fever or Night Sweats: A fever that lasts more than a day or two, or soaking night sweats [6].
- New Skin Changes: Specifically, painful, raised red nodules (often called Sweet’s syndrome), which can signal a flare of an underlying infection [7].
- New Lumps or Bumps: Any new or rapidly growing swollen lymph nodes in the neck, armpits, or groin [8].
- Unexplained Weight Loss: Losing weight without trying can be a sign of active infection or other complications [6].
Managing the “Scan Anxiety”
It is completely normal to feel anxious before blood tests or imaging. This “scan anxiety” is a common part of the survivor experience. Building a relationship with a care team that listens and responds quickly to your concerns can help reduce this burden. Managing AOID is about more than just medicine; it is about finding a balance between staying vigilant and reclaiming your daily life.
Common questions in this guide
Which vaccines are safe for me with AOID?
What are the warning signs of an AOID infection flare?
How will my doctors monitor my condition over time?
Why do I need to avoid gardening or hot tubs?
Does having AOID increase my risk for cancer?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our schedule for monitoring my anti-IFN-gamma autoantibody titers and B-cell counts?
- 2.How will we screen for long-term complications, such as B-cell lymphoma, over the next few years?
- 3.What specific 'dead' or recombinant vaccines am I allowed to receive safely, and when is the best time to get them relative to my rituximab doses?
- 4.If I develop a new fever or skin rash over the weekend, who do I call and what is the fastest way to get evaluated?
- 5.Are there certain environmental exposures (like specific hobbies or travel destinations) I should avoid right now?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (8)
- 1
Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States.
Hong GH, Ortega-Villa AM, Hunsberger S, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(1)):53-62 doi:10.1093/cid/ciz786.
PMID: 31429907 - 2
Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies.
Angkasekwinai N, Suputtamongkol Y, Phoompoung P, et al.
PloS one 2019; (14(4)):e0215581 doi:10.1371/journal.pone.0215581.
PMID: 31022229 - 3
Anti-interferon-gamma autoantibody and salmonellosis: Case report and literature review.
Towachiraporn S, Thongwitokomarn H, Salee P
IDCases 2024; (35()):e01926 doi:10.1016/j.idcr.2024.e01926.
PMID: 38298220 - 4
Development of intravascular large B-cell lymphoma during prophylactic antibiotic treatment for anti-interferon-gamma autoantibody syndrome: A case report.
Tanigaki T, Kimizuka Y, Maki Y, et al.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022; (28(11)):1562-1566 doi:10.1016/j.jiac.2022.07.015.
PMID: 35931413 - 5
Concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-γ autoantibodies.
Tsai WT, Cheng CY, Sun HY, et al.
Frontiers in immunology 2025; (16()):1526439 doi:10.3389/fimmu.2025.1526439.
PMID: 40313931 - 6
Anti-interferon-γ autoantibody syndrome mimicking lymphoproliferative disorders: a case series.
Ren D, Wee LEI, Lee SSM, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026; (170()):108860 doi:10.1016/j.ijid.2026.108860.
PMID: 42269920 - 7
Skin Manifestations in Patients with Adult-onset Immunodeficiency due to Anti-interferon-gamma Autoantibody: A Relationship with Systemic Infections.
Jutivorakool K, Sittiwattanawong P, Kantikosum K, et al.
Acta dermato-venereologica 2018; (98(8)):742-747 doi:10.2340/00015555-2959.
PMID: 29701234 - 8
Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies.
Krasaewes K, Patanadamrongchai N, Kaewpoowat Q, et al.
PLoS neglected tropical diseases 2025; (19(5)):e0012992 doi:10.1371/journal.pntd.0012992.
PMID: 40344159
This page provides educational information on managing Adult-Onset Immunodeficiency (AOID) long-term. Always consult your immunology team before making changes to your lifestyle, vaccines, or treatment plan.
Get notified when new evidence is published on Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.